JUL 1 0 2006 W



	U.S. Pater	Approved for use through 07/31/2006. OMB 0651-0031 at and Trademark Office; U.S. DEPARTMENT OF COMMERCE on of information unless it displays a valid OMB control number.
CMS Under the Paperwork Reduction Act of 1995	no persons are required to respond to a collection Application Number	on of information unless it displays a valid OMB control number. 10/720,790
TRANSMITTAL	Filing Date	November 21, 2003
FORM	First Named Inventor	David William Banner et al.
(to be used for all correspondence after initial	ling) Art Unit	1626
(Examiner Name	Andrew B. Freistein
	Attorney Docket Number	21500
Total Number of Pages in This Submission		21300
	ENCLOSURES (Check all that	
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks Statement of the Substan Under 37 C.F.R. 1.133(B)	After Allowance communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Ce of a Telephonic Interview
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name Signature Date Dayid E. Wildm	an,	
C	RTIFICATE OF TRANSMISSION	I/MAIL ING
I hereby certify that this correspondence is b	ing facsimile transmitted to the USPTO or	deposited with the United States Postal Service with tents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Typed or printed name Davig E. Wildman		
Signature //	o E Cide	Date July 6, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Confirmation No. 5703

David William Banner et al.

Group: 1626

Application No. 10/720,790, filed November 21, 2003

Examiner: Andrew B. Feirstein

(Case Docket No. 21500)

For: NOVEL MANDELIC ACID DERIVATIVES

STATEMENT OF THE SUBSTANCE OF A TELEPHONIC INTERVIEW UNDER 37 C.F.R. § 1.133(B)

Nutley, New Jersey 07110 July 6, 2006

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This Statement of the Substance of the Interview ("Statement") is filed in accordance with 37 C.F.R. § 1.133(b) in response to the Interview Summary received with the Notice of Allowance dated June 14, 2006. The deadline for filing this Statement is July 14, 2006. Applicants respectfully request entry of the enclosed Statement and consideration of the following remarks.

Appl. No. 10/720,790

Filed: November 21, 2003

REMARKS

During a telephonic interview between the Examiner and Applicants' representative on June 2, 2006, it was agreed that the Examiner would, by Examiner's amendment:

- 1. In claim 43, on page 209, on line 8 of the page, delete the species, "(RS)-2,6-Difluoro-4-trifluoromethanesulfonyloxy-phenyl)-ethoxy-acetic acid ethyl ester,".
- 2. In claim 43, on age 209, on lines 9-10 of the page, delete the species, "(RS)-4-(Ethoxy-ethoxycarbonyl-methyl)-3,5-difluoro-benzoic acid 2-trimethylsilanyl-ethyl ester,".
- 3. Cancel claims 64, 66 and 67.

No prior art was discussed. All of the pending claims were discussed with respect to the restriction requirement. It was agreed that upon entry of the Examiner's amendment, the subsisting claims would be allowed.

The foregoing Statement is in compliance with 37 C.F.R. § 1.133(b). No additional fees are believed due. However, the Director is hereby authorized to charge any deficit, or credit any overpayment, to Deposit Account No. 08-2525.

Appl. No. 10/720,790

Filed: November 21, 2003

If the Examiner believes there are any remaining issues a telephone call to the undersigned attorney is respectfully solicited.

Respectfully submitted,

Attorney for Applicant(s)

David E. Wildman (Reg. No. 40226) 340 Kingsland Street

Nutley, New Jersey 07110

Telephone: (973) 235-6385 Telefax: (973) 235-2363

245366